Hyogo-ken, Japan

Yoshiharu Ikeda


Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1997-2000

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Yoshiharu Ikeda: Pioneering Pharmaceutical Inventions

Introduction: Yoshiharu Ikeda, an accomplished inventor based in Hyogo-ken, Japan, has made significant contributions to the field of pharmaceuticals. With a total of two patents under his name, his work exemplifies a commitment to innovation in healthcare.

Latest Patents: Ikeda's latest patents include a groundbreaking invention related to a 2,3-diaminopropionic acid derivative. This compound, characterized by its chemical formula, presents promising applications as a platelet aggregation inhibitor, cancer metastasis inhibitor, wound healing agent, and bone resorption inhibitor. Additionally, he has developed dipiperidine derivatives that further enhance the therapeutic landscape, showcasing his versatility and expertise in medicinal chemistry.

Career Highlights: Yoshiharu Ikeda is affiliated with Sumitomo Pharmaceuticals Company Limited, where he has gained recognition for his innovative work. His contributions have played a crucial role in advancing pharmaceutical solutions that address significant medical challenges.

Collaborations: Throughout his career, Ikeda has collaborated with notable colleagues, including Yasuyuki Ueki and Toshio Nishihara. These partnerships have fostered a collaborative environment that has facilitated the exchange of ideas and accelerated the development of innovative solutions in the pharmaceutical industry.

Conclusion: Yoshiharu Ikeda's contributions to inventions in the pharmaceutical field demonstrate his dedication to improving healthcare outcomes. With his latest patents, he continues to pave the way for new therapeutic options, significantly impacting the lives of patients worldwide. His innovative spirit and collaborative efforts mark him as a key figure in the realm of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…